// App-Quantinova.ai

THU0395 : EFFICACY OF IXEKIZUMAB ON DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND OBJECTIVE SIGNS OF INFLAMMATION, STRATIFIED BY BASELINE CRP/SACROILIAC JOINT MRI STATUS

Researchers

Presenter

  • W. P. Maksymowych

Principal Investigators

  • H. Marzo-Ortega

  • M. ?stergaard

  • L. S. Gensler

  • J. Ermann

  • A. Deodhar

  • D. Poddubnyy

  • D. Sandoval

  • R. Bolce

  • A. Kronbergs

  • S. Liu Leage

  • G. Doridot

  • V. Geneus

  • A. Leung

  • D. Adams

  • M. Rudwaleit

Medical Centers

  • NIHR LBRC, LTHT and University of Leeds, Leeds, United Kingdom

  • University of Copenhagen, Copenhagen E, Denmark

  • University of California–San Francisco - California - United States of America

  • Brigham and Women's Hospital - Boston - United States of America

  • Oregon Health & Science University, Portland, United States of America

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Eli Lilly and Company, Indianapolis, United States of America

  • Syneos Health, Morrisville, NC, United States of America

  • Stadt Klinikum Bielefeld, Bielefeld, Germany

Locations

  • Canada

  • United Kingdom

  • Denmark

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Non-radiographic axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Sacroiliitis

  • Axial spondyloarthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Multinational

Phase

  • NA

Study Id's

  • NCT02757352

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved